Tempest Therapeutics, Inc.

NASDAQ (USD): Tempest Therapeutics, Inc. (TPST)

Last Price

1.45

Today's Change

+0.12 (9.02%)

Day's Change

1.33 - 1.46

Trading Volume

352,249

Overview

Market Cap

36 Million

Shares Outstanding

25 Million

Avg Volume

3,011,070

Avg Price (50 Days)

1.60

Avg Price (200 Days)

3.11

PE Ratio

-0.91

EPS

-1.60

Earnings Announcement

06-Nov-2024

Previous Close

1.33

Open

1.33

Day's Range

1.33 - 1.46

Year Range

0.17 - 9.77

Trading Volume

354,264

Price Change Highlight

1 Day Change

9.02%

5 Day Change

15.08%

1 Month Change

31.82%

3 Month Change

-52.15%

6 Month Change

-57.23%

Ytd Change

-67.12%

1 Year Change

190.00%

3 Year Change

-90.11%

5 Year Change

-98.46%

10 Year Change

-99.96%

Max Change

-99.91%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment